PPARA and Insulin resistance: Elafibranor, or GFT505, is a dual PPARα/δ agonist that showed promise in early clinical trials, leading to improved serum lipid profiles and insulin resistance in dyslipidemic and prediabetic/diabetic patients, respectively [147,148].